Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alterity Therapeutics Limited (ATH.AX)
AUD0.58
-0.03 (-4.17%)
AU ASX Healthcare Biotechnology
Address
460 Bourke Street 3000
Melbourne, VIC, AU
Melbourne, VIC, AU
CEO
David A. Stamler
Website
alteritytherapeutics.com
IPO
2000-03-28
ISIN AU0000043945
Also trades on
Australian Securities Exchange · ATH.AX (AUD)
NASDAQ Capital Market · ATHE (USD)
Other OTC · PRNAF (USD)
Description
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.58
-0.03 (-4.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
180.3K
Beta
-0.01
Float Shares
7.04B
Free Float %
64.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -10.00% | +12.50% | -10.00% | +12.50% | -18.18% | +12.50% | -68.97% | -89.29% | -98.20% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.58
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
15.21
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+35.3% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+63.5% ★ Q4'25: +134.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-281.6%
-
EBIT margin Biotechnology: +0.0%-269.6%
-
ROIC Biotechnology: -16.1%-771.7% Q4'25: -776.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+75.3% Q4'25: +306.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 3 Rev. Ana. 2 EPS Ana. |
Jun 2027 3 Rev. Ana. 2 EPS Ana. |
Jun 2028 3 Rev. Ana. 2 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
176.8K
est: 7.50M (-97.6%)
|
142.7K
est: 6.62M (-97.8%)
|
132.4K
est: 6.76M (-98.0%)
|
201.2K
est: 2.72M (-92.6%)
|
108.5K
est: 2.64M (-95.9%)
|
—
est: 3.13M (-100.0%)
|
4.34M
est: 3.87M (+12.1%)
|
5.12M
est: 4.47M (+14.7%)
|
3.92M
est: 4.53M (-13.6%)
|
4.02M
est: 3.90M (+3.1%)
|
5.44M
est: 9.30M (-41.5%)
|
4.80M
4.79M – 4.81M
-48.4% YoY
|
2.35M
2.35M – 2.35M
-51.1% YoY
|
9.20M
9.20M – 9.20M
+291.5% YoY
|
30.00M
30.00M – 30.00M
+226.1% YoY
|
96.92M
96.92M – 96.92M
+223.1% YoY
|
| EBITDA |
-10.57M
est: -7.50M (-41.0%)
|
-8.56M
est: -6.62M (-29.3%)
|
-6.86M
est: -6.76M (-1.5%)
|
-11.37M
est: -2.72M (-317.4%)
|
-12.77M
est: -2.64M (-383.6%)
|
-13.34M
est: -3.13M (-326.6%)
|
-19.36M
est: -3.87M (-400.3%)
|
-17.39M
est: -4.47M (-289.4%)
|
-17.51M
est: -4.53M (-286.5%)
|
-19.46M
est: -3.90M (-399.0%)
|
-14.63M
est: -9.30M (-57.3%)
|
-4.80M
-4.81M – -4.79M
+48.4% YoY
|
-2.35M
-2.35M – -2.35M
+51.1% YoY
|
-9.20M
-9.20M – -9.20M
-291.5% YoY
|
-30.00M
-30.00M – -30.00M
-226.1% YoY
|
-96.92M
-96.92M – -96.92M
-223.1% YoY
|
| EBIT |
-10.35M
est: -7.50M (-38.0%)
|
-8.59M
est: -6.62M (-29.6%)
|
-6.88M
est: -6.76M (-1.8%)
|
-8.20M
est: -2.72M (-200.9%)
|
-12.80M
est: -2.64M (-384.7%)
|
-13.46M
est: -3.13M (-330.2%)
|
-19.44M
est: -3.87M (-402.2%)
|
-17.45M
est: -4.47M (-290.7%)
|
-17.62M
est: -4.53M (-288.7%)
|
-19.61M
est: -3.90M (-402.7%)
|
-14.66M
est: -9.30M (-57.7%)
|
-4.80M
-4.81M – -4.79M
+48.4% YoY
|
-2.35M
-2.35M – -2.35M
+51.1% YoY
|
-9.20M
-9.20M – -9.20M
-291.5% YoY
|
-30.00M
-30.00M – -30.00M
-226.1% YoY
|
-96.92M
-96.92M – -96.92M
-223.1% YoY
|
| Net Income |
-5.89M
est: -159.92M (+96.3%)
|
-7.73M
est: -1.98B (+99.6%)
|
-7.54M
est: -3.20B (+99.8%)
|
-8.27M
est: -85.30M (+90.3%)
|
-11.96M
est: -83.16M (+85.6%)
|
-10.06M
est: -65.04M (+84.5%)
|
-15.31M
est: -63.97M (+76.1%)
|
-12.85M
est: -56.15M (+77.1%)
|
-13.81M
est: -22.50M (+38.6%)
|
-19.12M
est: -31.98M (+40.2%)
|
-12.15M
est: -16.87M (+28.0%)
|
-6.44M
-6.44M – -6.44M
+61.9% YoY
|
-7.96M
-7.96M – -7.96M
-23.8% YoY
|
-8.07M
-8.07M – -8.07M
-1.3% YoY
|
-10.09M
-10.09M – -10.09M
-25.1% YoY
|
1.48M
1.48M – 1.48M
+114.7% YoY
|
| SGA |
4.15M
est: 9.37M (-55.7%)
|
3.59M
est: 8.28M (-56.6%)
|
3.95M
est: 8.44M (-53.2%)
|
4.32M
est: 3.40M (+26.9%)
|
4.28M
est: 3.30M (+29.7%)
|
3.33M
est: 3.91M (-14.7%)
|
6.87M
est: 4.83M (+42.1%)
|
5.82M
est: 5.58M (+4.4%)
|
5.22M
est: 5.66M (-7.8%)
|
4.76M
est: 4.87M (-2.3%)
|
5.48M
est: 11.62M (-52.8%)
|
6.00M
5.99M – 6.02M
-48.4% YoY
|
2.94M
2.94M – 2.94M
-51.1% YoY
|
11.49M
11.49M – 11.49M
+291.5% YoY
|
37.48M
37.48M – 37.48M
+226.1% YoY
|
121.08M
121.08M – 121.08M
+223.1% YoY
|
| EPS |
-0.01
est: -0.03 (+53.2%)
|
-0.01
est: -0.31 (+95.3%)
|
-0.01
est: -0.50 (+97.2%)
|
-0.02
est: -0.01 (-16.2%)
|
-0.02
est: -0.01 (-49.2%)
|
-0.01
est: -0.01 (-6.2%)
|
-0.01
est: -0.01 (+10.0%)
|
-0.01
est: -0.01 (+39.6%)
|
-0.01
est: 0.00 (-62.0%)
|
-0.01
est: -0.01 (-4.0%)
|
0.00
est: 0.00 (+27.9%)
|
0.00
0.00 – 0.00
+61.9% YoY
|
0.00
0.00 – 0.00
-23.8% YoY
|
0.00
0.00 – 0.00
-1.3% YoY
|
0.00
0.00 – 0.00
-25.1% YoY
|
0.00
0.00 – 0.00
+114.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-18.88M
OE per share TTM
0.00
Owner's Yield
-20.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-14.7K
Shares Outstanding
10.88B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David A. Stamler | CEO & Director | 1M | — |
| Abby Macnish Niven | Chief Financial Officer & Company Secretary | — | female |
| Robert Cherny | Head of Research | — | — |
| Rudolph Emile Tanzi | Chief Scientific Advisor and Member of Research & Development Advisory Board | — | — |
| Steven D. Targum | Chief Medical Advisor | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATH.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
